Skip to contentpdufa.bio

Fresenius Kabi: 6 Complete Response Letters

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

The FDA's CRL release (openFDA transparency/crl, last updated 2026-11-18; snapshot read 2026-11-21) holds 6 Complete Response Letters to this company, dated 2023 to 2026, on 4 applications; 2 of them received more than one. The FDA releases letters selectively, so this may not be every letter the company received. Printed in the release as: Fresenius Kabi USA, LLC (6).

Grouped on the company name as openFDA prints it, with capitalization, accents, punctuation and corporate-form words (Inc., LLC, Ltd., Limited, Corp., SA, USA and the like) ignored; each row shows the name as printed. A misspelled name forms its own group, and a letter printed with a heading or a bare corporate-form word where the name should be is on no company page, so a count here can be lower than the letters the release holds for a company. Facts only: no view on any outcome.

Letter dateApplicationName as printedopenFDA statusOrange Book approval after the letterSections the letter names
July 29, 2026NDA 220381/Original 2, NDA 220381Fresenius Kabi USA, LLCApprovednone listed after the letternone read
February 27, 2026NDA 214610Fresenius Kabi USA, LLCUnapprovednone listed after the letterProduct Quality
February 27, 2026NDA 215818Fresenius Kabi USA, LLCUnapprovednone listed after the letterProduct Quality
April 25, 2025NDA 215818Fresenius Kabi USA, LLCUnapprovednone listed after the letterProduct Quality
December 11, 2024NDA 214610Fresenius Kabi USA, LLCUnapprovednone listed after the letterProduct Quality
May 31, 2023BLA 761275Fresenius Kabi USA, LLCApprovednot in the Orange Book (a BLA)none read

How each column is made: the letter date and the PDF are the FDA's release; "openFDA status" is openFDA's approval_status field as released; "Orange Book approval" is the earliest approval date the FDA's Orange Book products file (FDA files dated 2026-11-13) lists for the NDA, shown when it falls after the letter date and the letter is not on a supplement; BLAs are not in the Orange Book, so no date is shown for them; "sections" are the letter's own deficiency headings read from its PDF text layer, for letters dated 2024 or later whose PDF holds no other letter from the release ("none read" otherwise, or where no heading could be read).

Every company in the release · facts from all released CRLs · every released letter